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SUMMARY
By building reconstruction models for a case of gastroenteritis in the general population moving
through diﬀerent steps of the surveillance pyramid we estimated that millions of illnesses occur
annually in the European population, leading to thousands of hospitalizations. We used data on the
healthcare system in seven European Union member states in relation to pathogen characteristics
that inﬂuence healthcare seeking. Data on healthcare usage were obtained by harmonized
cross-sectional surveys. The degree of under-diagnosis and underreporting varied by pathogen and
country. Overall, underreporting and under-diagnosis were estimated to be lowest for Germany and
Sweden, followed by Denmark, The Netherlands, UK, Italy and Poland. Across all countries, the
incidence rate was highest for Campylobacter spp. and Salmonella spp. Incidence estimates resulting
from the pyramid reconstruction approach are adjusted for biases due to diﬀerent surveillance
systems and are therefore a better basis for international comparisons than reported data.
Key words : Campylobacter, gastrointestinal infections, incidence, public health, Salmonella.
INTRODUCTION
There is an increasing interest in assessing the burden
of foodborne disease [1–3]. Valid and representative
data on the incidence of speciﬁc pathogens causing
gastroenteritis are key components of these assess-
ments. However, reported data, which are largely
based on passive surveillance, underestimate the true
incidence. Underreporting and under-diagnosis con-
tribute to this problem. Under-diagnosis is the failure
of the healthcare system to capture cases in the
community that do not seek medical advice (i.e. the
number of cases seeking medical attention divided by
the total number of cases in the population) [1].
* Author for correspondence : J. A. Haagsma, Erasmus MC,
PO Box 2040, 3000 CA Rotterdam, The Netherlands.
(Email : j.haagsma@erasmusmc.nl)
# Additional members of the Working Group are given in the
Appendix.
Epidemiol. Infect. (2013), 141, 1625–1639. f Cambridge University Press 2012
doi:10.1017/S0950268812002166
Health outcomes caused by infectious gastroenteritis
vary from mild to very severe and recorded diseases
often represent only the tip of the iceberg (i.e. sur-
veillance pyramid) of all disease in a particular region.
Underreporting refers to cases that have sought
medical advice but are not correctly diagnosed,
classiﬁed, notiﬁed, or disseminated to surveillance
authorities (i.e. the number of cases correctly diag-
nosed, classiﬁed, notiﬁed, or disseminated to surveil-
lance authorities divided by the total number of cases
seeking medical attention) [1]). The degree of under-
reporting and under-diagnosis varies by pathogen and
by country, due to diﬀerences in routinely investi-
gated pathogens, diﬀerences in healthcare use and
diﬀerences in laboratory practice and surveillance.
A few cohort studies provide insight into the degree
of underreporting and under-diagnosis (the ‘multi-
plier ’) of disease caused by gastrointestinal patho-
gens. In England andWales, the IID1 study estimated
that in 1993–1996 there were 3.2 cases of salmonel-
losis in the population for every case reported to
national surveillance [4]. The recently published IID2
study indicated that in 2008–2009, this multiplier had
increased to 4.7. Possible reasons for this include a
general decrease in use of General Practitioner (GP)
services by gastroenteritis patients in particular be-
cause of increased self-management and possibly a
decrease in symptom severity [5]. In The Netherlands,
based on the Sensor study in 1999, the multiplier for
salmonellosis was estimated as 13.4 [6, 7]. A recent
study, based on disease risks in Swedish travellers
estimated that for the European Union (EU) as a
whole, the multiplier for salmonellosis was 58, but
ranged between 0.4 and 2000 in diﬀerent countries [8].
Even though such cohort studies provide valuable
data for the calibration of surveillance data, they are
highly demanding on resources and this prevents
them from being performed in more countries.
As an alternative, several research groups have
conducted studies that explicitly reconstruct the
surveillance pyramid to estimate the degree of under-
reporting and under-diagnosis by estimating the
proportion of patients who would visit their GP, and
would submit a faecal specimen [9, 10]. The recon-
struction models also include estimates of laboratory
practice (i.e. if particular pathogens are analysed, and
if positive samples are reported to national surveil-
lance authorities). These studies have typically ad-
dressed a speciﬁc pathogen, i.e. Shiga toxin-producing
E. coli O157 (STEC) in Canada [11]. Some studies
have taken multiple pathogens into account in a
region or country, i.e. Ontario, Canada [12], Australia
[13] or the USA [1]. Due to diﬀerences in details of the
reconstruction approach, the results of these studies
cannot directly be compared. The scope of this study
is to develop a transparent model to reconstruct the
surveillance pyramid for seven pathogens that cause
gastroenteritis in seven EU member states, which can
serve as a basis for prioritization of foodborne and
zoonotic hazards in the EU.
METHODS
Countries
Germany (DE), Denmark (DK), Italy (IT), The
Netherlands (NL), Poland (PL), Sweden (SE) and the
United Kingdom (UK) participated in the study, as
these countries had previously conducted telephone
surveys allowing for estimation of key parameters
that are necessary for reconstruction of the surveil-
lance pyramid.
Pathogens
Based on availability of routine surveillance data
in the participating countries, Campylobacter spp.
(Camp), Salmonella spp. (Salm), Yersinia entero-
colitica (Yers), Shigella spp. (Shig), Shiga-toxin
producing Escherichia coli O157 (STEC), entero-
pathogenic Escherichia coli (EPEC), and Crypto-
sporidium spp. (Cryp) were selected for analysis. Not
all countries had data for all pathogens.
Reconstruction model parameters
The model consists of sets of country-speciﬁc and
pathogen-speciﬁc parameters. All but one of these
parameters are represented by beta distributions
and were based on observed data in the diﬀerent
countries. Table 1 provides an overview of the sets of
country-speciﬁc and pathogen-speciﬁc parameters.
Country-speciﬁc parameters in Table 1 will result in
diﬀerent multipliers. It is assumed that the probability
of visiting a GP, and of submitting a sample for lab-
oratory analysis diﬀers for patients with bloody and
non-bloody diarrhoea. Other potential determinants
of GP visits or sample submission, such as duration of
illness and age of the patient, were not taken into
account, because no data were consistently available.
Pathogen-speciﬁc parameters were assumed not to
vary between countries, but result in diﬀerent
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multipliers for pathogens within one country. The
probability of submitting a stool sample for a hospi-
talized patient was modelled separately, and was not
assumed to depend on the nature of the diarrhoeal
illness. The probability of analysing a submitted stool
sample for a speciﬁc pathogen was assumed to vary
between countries as well as between pathogens, and
also to depend on the origin of the sample. Reporting
positive laboratory results was assumed to vary de-
pending on the origin of the sample. The sensitivity of
laboratory methods and the proportion of patients
with bloody diarrhoea were assumed to vary between
pathogens, but not by country.
Model equations
The reconstruction model estimates the probability
for a case of gastroenteritis by a speciﬁc pathogen in
the general population to move through diﬀerent
steps of the surveillance pyramid (i.e. the probability
of visiting a GP, the probability of submitting a
stool sample for a consulting patient/hospitalized
patient, the probability of analysing a pathogen in
samples of a consulting patient/hospitalized patient,
and the probability of reporting a positive laboratory
result for a consulting patient/hospitalized patient).
Ultimately, the reconstruction model estimates the
multiplier for each reported case to the number of
symptomatic cases in the population. The model
equations are presented in Table 2. The source of data
for the model are laboratory-diagnosed cases re-
ported to national surveillance and the number of
these who are hospitalized. The reconstruction model
estimates the probability of a case at diﬀerent layers
of the surveillance pyramid. Uncertainty in the results
of the reconstruction model was explored by Monte
Carlo simulations and the reconstruction model was
validated by comparison to the results of previously
performed independent studies that used other study
designs (population-based surveys).
Data
The annual number of reported cases per pathogen
and per country was obtained from national surveil-
lance systems. To moderate the eﬀect of annual vari-
ation in incidence, the average number of reported
cases in the years 2001–2005 was used. Data were
corrected for the coverage of the surveillance network
if the surveillance network did not cover the entire
population of a country. In Italy, the surveillance
network covered three provinces. Hence, it was
decided to limit the study to these three provinces.
In The Netherlands, Camp and Salm data were
extrapolated from the whole country by applying
scaling factors which corrected for surveillance
Table 1. Parameters used in the pyramid reconstruction model
Symbol Description Distribution
Country-speciﬁc parameters
Probability of visiting a GP with :
a $ Bloody diarrhoea Beta(a1;a2)
b $ Non-bloody diarrhoea Beta(b1;b2)
Probability of submitting a stool sample for a consulting patient with :
c $ Bloody diarrhoea Beta(c1;c2)
d $ Non-bloody diarrhoea Beta(d1;d2)
e Probability of submitting a stool sample for a hospitalized patient Beta(e1;e2)
Probability of analysing a pathogen* in samples for :
f $ Patients visiting a GP Beta(f1;f2)
g $ Hospitalized patients Beta(g1;g2)
Probability of reporting a positive laboratory result for :
h $ Patients visiting a GP Beta(h1;h2)
i $ Hospitalized patients Beta(i1;i2)
Pathogen-speciﬁc parameters
j Sensitivity of laboratory analysis
$ Campylobacter, Salmonella, Yersinia, Shigella Triang(j3;j4;j5)
$ STEC, EPEC, Cryptosporidium Beta(j1;j2)
k Proportion of bloody diarrhoea in population cases Beta(k1;k2)
GP, General Practitioner ; STEC, Shiga toxin-producing E. coli O157; EPEC enteropathogenic Escherichia coli.
* Diﬀerent within a country for each pathogen.
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network coverage. The data were obtained from the
following sources :
. DE : Surveillance data were obtained from the
national level database SurvNet (accessed 23 April
2008), hosted at the federal national health auth-
ority, the Robert Koch Institute (RKI) in Berlin.
With implementation of the Protection against
Infection Act (Infektionsschutzgesetz, IfSG; http://
bundesrecht.juris.de/ifsg/index.html) in 2001, the
seven pathogens belong to a list of 47 pathogens for
which a laboratory-conﬁrmed acute infection is
notiﬁable to the local health department (LHD) by
the investigating laboratory. After veriﬁcation of a
case according to national case deﬁnitions the LHD
forwards the case electronically via the state health
department to the RKI [14].
. DK : Case numbers were obtained from national
surveillance from the Register of Enteric Pathogens
[15]. The number of hospitalized cases was based on
Helms et al. [16].
. IT : Case numbers for Salm were obtained from the
national oﬃcial surveillance. Data for Camp,
available only for limited areas of the country,
were obtained from the laboratory surveillance
network for enteric pathogens (Enter-Net Italia ;
http://www.salute.gov.it/malattieInfettive/pagina
InternaMenuMalattieInfettive. jsp?id=812&menu=
strumentieservizi.). The number of hospitalized cases
were obtained from the hospital discharge database.
. NL : Case numbers and number of hospitalized
cases per pathogen were obtained from laboratory
surveillance [17].
. PL : Case numbers and number of hospitalized
cases per pathogen were obtained from the national
comprehensive surveillance system based on man-
datory notiﬁcations of physicians of all suspected
and diagnosed cases ; the reported ﬁve pathogens
belonged to 79 diseases and syndromes under
surveillance during 2002–2008.
. SE : Case numbers and number of hospitalized
cases per pathogen were obtained from surveillance
data [18] and database of closed medical care
records.
. UK : Case numbers and number of hospitalized
cases per pathogen were obtained from surveillance
data [4].
The country-speciﬁc parameters on GP visits and
sample submission were derived from harmonized
cross-sectional surveys of acute gastroenteritis inci-
dence in the community. All studies used a similar
design and the same case deﬁnition. A case of gas-
troenteritis was deﬁned as a person with at least three
loose stools, or any vomiting, in 24 h, in the 4 weeks
prior to completion of the questionnaire, but exclud-
ing those (a) with cancer of the bowel, irritable bowel
syndrome, Crohn’s disease, ulcerative colitis, celiac
disease, or another chronic illness with symptoms of
diarrhoea or vomiting, or (b) who report their symp-
toms were due to drugs, alcohol, or pregnancy. In
each of these surveys, randomly selected residents of
private households were contacted either by telephone
(DE, DK, IT, PL, UK) or by mail (NL, SE). The
studies were carried out in 2008 and 2009 and were
reported in detail elsewhere ([5, 19–22] ; unpublished
Table 2. Model for reconstructing the surveillance pyramid for a speciﬁc pathogen in a speciﬁc country*
Symbol Description Formula
nR Number of reported cases per year# Data
nH Number of hospitalized cases per year Data
nGP Number of cases who are not hospitalized, but visit a GP nR – nH
p Probability of visiting a GP with gastroenteritis k.a+(1 – k)b
m Probability of submitting a stool sample when visiting a GP k.c+(1 – k)d
Probability of reporting a case for
n $ Patients visiting a GP m.f.j.h
o $ Hospitalized patients e.g.j.i
NGP Total number of cases visiting a GP nGP/n
NH Total number of hospitalized cases nH/o
NP Total cases in the population (NGP+NH)/p
NGP– Cases in the population who do not visit a GP NP – (NGP+NH)
M Multiplier NP/nR
GP, General Practitioner.
* Model parameters are further described in Table 1.
# Average for 2001–2005 when available.
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data, Germany). The probability of submitting a
sample for hospitalized patients was based on the
cross-sectional survey of gastroenteritis in DE and IT,
expert opinion in DK, SE, and IT [23], the GEOPS
study in NL [24, 25], a health utilization survey in PL
[26], a cross-sectional survey in SE (F. Hansdotter,
personal communication) and the IID studies in UK.
As the study period for this paper (2001–2005) was in
between the time of execution of the IID1 [27] and
IID2 [28] studies, the mean value of the results from
the two studies was used. The probability of analysing
a sample for a speciﬁc pathogen was based on expert
opinion, except for NL and IT where survey data were
available [29]. Data on the probability of reporting
a pathogen was based on expert opinion for all
countries. When using expert opinion, subjective beta
distributions were deﬁned with parameters chosen to
reﬂect the degree of conﬁdence in the estimates.
To assess the proportion of bloody diarrhoea per
pathogen a literature review was performed. Details
are provided in Annex B (available online). The
sensitivity of laboratory tests was based on Ethelberg
et al. [30] for Camp, Salm, Yers and Shig; expert
opinion for STEC and EPEC and Weber et al. [31]
for Cryp. Uncertainty was expressed by beta or
triangular distributions.
Uncertainty analysis
Stochastic models were built using @RISK 5.7
(Palisade Corporation, USA), a Monte Carlo simu-
lation add-in to Microsoft Excel. The model was run
for 10 000 iterations to stabilize the output distri-
butions. Median values from the output distributions
and 95% credible intervals were reported.
RESULTS
Reported cases
The average annual number of reported cases per
pathogen and country is shown in Table 3. For IT,
data on Camp were only available for three provinces,
and the results are also reported for these provinces
(with 2 million inhabitants). For the UK, data were
used for England only.
Country-speciﬁc parameters
The median values of the country-speciﬁc parameters
are shown in Table 4a. Details of distribution func-
tions are shown in Annex A (available online). The
probability of visiting a GP and submitting a stool
sample was greater for cases with bloody diarrhoea
Table 3. Reported cases per year by pathogen and by country (average 2001–2005)
Pathogen DE DK IT NL PL SE UK*
Inhabitants (r106) 83.5 5.4 57.7# 16.2 38.2 9.0 50.0
Total cases
Campylobacter 55 355 3987 475# 6541 10 600 7176 47 968
Salmonella 64 380 2,007 9888 2747 13 531 3916 14 025
Yersinia 6624 248 — 430 135 692 25
Shigella 1181 146 — 329 60 468 1190
STEC 104 138 — 140 — 102 738
EPEC 3497 457 — — 1129 — —
Cryptosporidium 1084 — — 314 — — 4128
Hospitalized
Campylobacter 6459 429 69# 1177 6400 619 2399
Salmonella 13 162 356 4253 694 9548 393 420
Yersinia 1093 23 — 5 91 65 0.1
Shigella 156 20 — 24 38 36 29
STEC 26 11 — 21 2 44 280
EPEC 566 46 — — 866 — —
Cryptosporidium 83 — — 10 — — 10
DE, Germany; DK, Denmark; IT, Italy ; NL, The Netherlands ; PL, Poland; SE, Sweden; UK, United Kingdom.
STEC, Shiga toxin-producing E. coli O157; EPEC enteropathogenic Escherichia coli.
— , No data.
* Data for England only.
# For Campylobacter, data from three provinces only (2 million inhabitants) were available.
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than for cases with non-bloody diarrhoea (except
submission of stool samples in SE; there was con-
siderable uncertainty in this estimate due to a small
sample size). The probability of visiting a GP was
smaller in NL than in other countries, but the prob-
ability of submitting a sample was notably higher
in that country for cases with bloody diarrhoea. The
probability of submitting a stool sample in PL was
considerably lower than in other countries. Salm and
Shig were commonly tested for in samples from the
GP (with lower estimates for NL), whereas testing for
Camp was common in some (DE, DK, SE) but less so
in other (IT, NL, PL) countries. Other pathogens
were typically tested for in less than 50% of samples,
except testing for Yers in SE. In samples from hospi-
tals, pathogen testing was as frequent as or more
frequent than in samples from GPs. Reporting of
positive results was assumed to take place with high
probability, except for IT.
Pathogen-speciﬁc parameters
The median values of the pathogen-speciﬁc par-
ameters are shown in Table 4b. There is very little
information on the performance characteristics of
routine methods in medical microbiological labora-
tories. The sensitivity of isolating Camp, Salm, Yers
and Shig was between 63% and 88%, based on data
from DK. Such data were not available for STEC and
EPEC and was assumed to be in the same range as the
bacteria, i.e. median value of 71% (see Annex A,
Table A2). To stress the uncertainty in this estimate, a
beta distribution with a wide conﬁdence interval was
Table 4a. Median values of country-speciﬁc parameters
Parameter Short description DE DK IT NL PL SE UK
a Visit GP, bloody 0.51 0.61 0.50 0.31 0.63 0.61 0.22
b Visit GP, non-bloody 0.34 0.13 0.36 0.08 0.28 0.08 0.16
c Submit sample, bloody 0.50 0.29 0.50 0.82 0.23 0.39 0.30
d Submit sample, non-bloody 0.34 0.18 0.01 0.10 0.02 0.48 0.19
e Submit sample, hospital 0.75 0.93 0.82 0.89 0.70 0.84 0.29
f Analyse sample, GP
Campylobacter 0.99 0.99 0.52 0.87 0.61 0.99 1.00
Salmonella 0.99 0.99 0.91 0.84 0.99 0.99 1.00
Yersinia 0.61 0.99 — 0.56 0.29 0.87 0.02
Shigella 0.99 0.99 — 0.78 0.61 0.99 1.00
STEC 0.29 0.39 — 0.09 0.50 0.50 1.00
EPEC 0.29 0.29 — — — — —
Cryptosporidium 0.18 — — 0.11 — — 1.00
g Analyse sample, hospital
Campylobacter 0.99 0.99 0.52 0.99 0.61 0.99 0.99
Salmonella 0.99 0.99 0.91 0.99 0.99 0.99 0.99
Yersinia 0.61 0.99 — 0.20 0.29 0.87 0.02
Shigella 0.99 0.99 — 0.99 0.61 0.99 0.99
STEC 0.29 0.39 — 0.82 0.50 0.60 0.99
EPEC 0.29 0.29 — — — — —
Cryptosporidium 0.18 — — 0.18 — — 0.99
h Report result, GP 0.99 0.99 0.71 1.00 0.71 0.99 0.69
i Report result, hospital 0.99 0.99 0.82 1.00 0.93 0.99 0.98
DE, Germany; DK, Denmark; IT, Italy ; NL, The Netherlands ; PL, Poland; SE, Sweden; UK, United Kingdom.
GP, General Practitioner ; STEC, Shiga toxin-producing E. coli O157; EPEC enteropathogenic Escherichia coli.
—, No data.
Table 4b. Median values of pathogen-speciﬁc
parameters
Pathogen
Sensitivity of
diagnostic
method
Proportion of
patients with
bloody diarrhoea
Campylobacter 76% 17%
Salmonella 88% 37%
Yersinia 78% 33%
Shigella 63% 25%
STEC 71% 85%
EPEC 71% 25%
Cryptosporidium 50% 1%
STEC, Shiga toxin-producing E. coli O157; EPEC
enteropathogenic Escherichia coli.
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generated. The microscopy methods used for Cryp are
generally less sensitive and an average of 50% was
used. Uncertainty distributions are presented in
Figure 1 (details can be found in Annex A).
The proportion of bloody diarrhoea in population
cases, based on the literature survey is presented in
Figure 2. As no data were available for EPEC, data
for Shig were used as a proxy. With a median of 85%
of cases with bloody diarrhoea, the highest pro-
portion of bloody diarrhoea was caused by STEC.
The median proportions of bloody diarrhoea due to
Salm, Yers, Shig/EPEC, and Camp were 37%, 33%,
25% and 17%, respectively. The lowest proportion of
bloody diarrhoea was associated with Cryp (1%).
Further details of the review are given in Annex B.
Pyramid reconstruction
In Figure 3a, the stepwise reconstruction of the
pyramid for Salm is presented. Only the reporting
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Cryptosporidium Salmonella
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Fig. 1. Uncertainty of the sensitivity of isolating gastrointestinal pathogens. STEC, Shiga toxin-producing E. coli O157;
ETEC/EPEC, enterotoxigenic Escherichia coli/enteropathogenic Escherichia coli.
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0·5 0·6 0·7 0·8 0·9 1·0
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Campylobacter Shigella/ EPEC
Yersinia
Cryptosporidium
Fig. 2. Uncertainty distribution of the proportion of bloody diarrhoea in patients with gastroenteritis, per pathogen. STEC,
Shiga toxin-producing E. coli O157; EPEC enteropathogenic Escherichia coli.
Community incidence of gastroenteritis 1631
process for patients in the GP stream was re-
constructed. This results in multipliers that are
slightly diﬀerent from those reported elsewhere, as the
hospital stream is not taken into account. In the
ﬁgures, the number of patients in diﬀerent layers of
the pyramid is presented as a fraction of the total
number of cases in the general population, which is set
to 1. It can be seen that there are substantial diﬀer-
ences in the fraction of patients who visit their GP.
The fraction is lowest in NL and UK (17% and 18%,
respectively) and highest in DE, IT and PL and
(40%, 41% and 41%, respectively). This diﬀerence is
propagated in the next steps of the pyramid. To take
into account the diﬀerence between countries in
further steps, the slope of the connecting lines should
be evaluated. Hence, the largest impact of the pro-
portion of GP patients who submit a stool sample is
observed in PL and UK (4%).
For comparison, Figure 3b presents the pyramid
for Cryp. Only three countries have reconstructed the
surveillance pyramid for this pathogen. Multipliers
are relatively high because Cryp rarely causes bloody
diarrhoea. Moreover, limited testing and lower test
sensitivity have an impact on the multipliers.
Patient in 
population
Visit GP Submit stool 
sample GP
Sample 
analysed
Sample 
tested +ve
Result 
reported
Patient in 
population
Visit GP Submit stool 
sample GP
Sample 
analysed
Sample 
tested +ve
Result 
reported
1·000
0·100
0·010
DE
DK
IT
NL
PL
SE
UK
0·001
0·000
1·0000
0·1000
0·0100
0·0010
0·0001
UK
NL
DE
(a)
(b)
Fig. 3. (a) Stepwise reconstruction of the surveillance pyramid for Salmonella spp. (b) Stepwise reconstruction of the sur-
veillance pyramid for Cryptosporidium spp. GP, General Practitioner ; DE, Germany; DK, Denmark; IT, Italy ; NL, The
Netherlands ; PL, Poland; SE, Sweden; UK, United Kingdom.
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Population incidence and multipliers
Table 5 shows the median number of reported cases
and multipliers that result from the reconstruction of
the surveillance pyramid per country and pathogen.
The data are shown graphically in Figure 4 (see
graphical reconstruction of the surveillance pyramid
for all pathogens in online Annex C). Multipliers
diﬀer widely. For example, in DE in the period
2001–2005 an average 64 380 Salm cases were re-
ported annually. The multiplier for Salm in DE was
6.7. This means that an estimated 430 000 cases of
salmonellosis occurred in the general population (520
cases/100 000 inhabitants). In PL, only 13 531 cases of
Salm were reported, but the multiplier for Salm was
approximately ten times higher than in DE. Hence,
832 000 cases of salmonellosis were estimated to
occur in the general population (2200 cases/100 000
inhabitants). Overall, multipliers were lowest for
DE and SE, followed by DK, NL, IT, UK and PL.
Based on medians of the (median) results for all
countries, the incidence rate was highest for Camp,
followed by Salm while incidence rates of Yers, Shig
and STEC were lower and of the same magnitude.
Between 16% and 32% of all cases in the population
consulted their GP, and 1–3% were hospitalized.
These proportions were highest for Salm and lowest
for Camp and Shig. In individual countries, results
usually diﬀered by no more than a factor of 2 from the
median across countries, with some notable excep-
tions. The incidence rate of Salm in PL was clearly
larger than the median at all levels of the pyramid due
to high multipliers. The incidence rate of Camp in
DE, and of Shig in DE and PL at the population
and GP level, but not at hospital level, was clearly
lower than the median. The incidence rates of STEC
Table 5a. Median values of multipliers and incidence rates per country and per pathogen
Country … DE DK IT* NL PL SE UK Median
Campylobacter Multiplier 9.3a 29b 100b 49b 72c 17b 52a —
Population 620a 2200b 2300b 2000b 2000c 1400b 5000a 2200
GP 220a 430b 870b 220a 617c 220a 830a 430
Hospital 14a 12a 14b 11a 50c 11b 24a 14
Salmonella Multiplier# 6.7a 17b 17b 20b 18c 10b 40a —
Population$ 520a 620b 290b 340b 633c 440b 1100a 520
GP$ 180a 160b 100b 47b 189c 100b 200a 160
Hospital$ 25a 8.4a 16b 5.5a 58c 6.2b 5.2a 8.4
Yersinia Multiplier 13b 20b — 46b 71c 13.6b 2200b —
Population 100b 93b — 120b 406c 110b 110b 110
GP 37b 25b — 18a 154c 24b 20a 24
Hospital 3.9b 0.5a — 0.2c 2.4b 1.4b 0.1d 1.0
Shigella Multiplier 11a 30b — 53b 65c 18b 61a —
Population 15a 82b — 110b 10c 94b 150a 88
GP 5.3a 18b — 14b 3c 17b 25a 17
Hospital 0.4a 0.7a — 0.3a 0.4b 0.8b 0.4a 0.45
STEC Multiplier 23b 33d — 87b — 13b 34b —
Population 2.2b 85d — 76b — 15b 50b 50
GP 1.1b 37d — 19b — 5.1c 6.8b 6.8
Hospital 0.2b 0.9b — 0.3b — 1.6b 3.1b 0.9
EPEC Multiplier 34b 100c — — — — — —
Population 140b 870c — — — — — 505
GP 48b 200c — — — — — 124
Hospital 4.8b 5.0b — — — — — 4.9
Cryptosporidium Multiplier 100c — — 2100b — — 93b —
Population 130c — — 4000b — — 770b 770
GP 43c — — 330b — — 130b 130
Hospital 1.6c — — 0.8c — — 0.2b 0.8
DE, Germany; DK, Denmark; IT, Italy ; NL, The Netherlands ; PL, Poland; SE, Sweden; UK, United Kingdom.
GP, General Practitioner ; STEC, Shiga toxin-producing E. coli O157; EPEC enteropathogenic Escherichia coli.
* Data from three provinces in Italy.
# CV (coeﬃcient of variation=standard deviation/mean) : a CV<0.25, b 0.25fCV<1.0, c 1.0fCV<4.0, d CVo4.0.
$ Incidence rate/100 000 person-years.
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diﬀered strongly between countries, with low values
in DE, intermediate values in SE and high values in
DK and NL. The number of reported cases in
DE (0.12/100 000) was clearly lower than for NL
(0.86/100 000) and in particular DK (26/100 000).
Furthermore, the multiplier in DE (30) was also lower
than in DK (74) and NL (120). In NL, only 9% of all
STEC patients submitted a faecal sample for analysis
(see Table 4a). Results for EPEC were only available
for two countries.
Uncertainty analysis
The uncertainty in the model outputs is indicated in
Table 5 by subscripts that indicate the magnitude of
the coeﬃcient of variation (CV, details are provided
in Annex C). For many results, the CV was between
typically between 0.25 and 1.0 for incidence rates at
population and GP level, as well as for the multiplier.
The CV of the incidence rate in hospitals was typically
<0.25, because in this estimate less uncertain
Table 5b. Median annual number of infections per country and per pathogen
Country … DE DK IT NL PL SE UK
Inhabitants (r106) 83.5 5.4 57.7* 16.2 38.2 9 50
Campylobacter Population 515 000 116 000 156 000 322 000 765 000 122 000 2 500 000
GP 178 000 23 000 54 000 36 000 236 000 19 000 416 000
Hospital 12 000 640 8700 1700 19 000 1000 12 000
Salmonella Population 430 000 33 000 34 000 55 000 242 000 40 000 563 000
GP 151 000 8600 8900 7700 72 000 9300 98 000
Hospital 20 000 606 250 890 22 000 560 2600
Yersinia Population 86 000 5000 — 20 000 9600 9500 55 000
GP 30 000 1300 — 2900 3400 2200 9800
Hospital 3200 30 — 40 310 120 40
Shigella Population 12 000 4400 — 17 000 3900 8400 72 000
GP 4400 970 — 2300 1300 1600 12 000
Hospital 440 40 — 40 140 70 180
STEC Population 2400 4600 — 12 000 — 1360 25 000
GP 890 2000 — 3000 — 450 3400
Hospital 180 50 — 40 — 140 1500
EPEC Population 117 000 47 000 — — — — —
GP 40 000 11 000 — — — — —
Hospital 4000 270 — — — — —
Cryptosporidium Population 109 000 — — 651 201 — — 385 961
GP 35 000 — — 54178 — — 62698
Hospital 1400 — — 134 — — 77
DE, Germany; DK, Denmark; IT, Italy ; NL, The Netherlands ; PL, Poland; SE, Sweden; UK, United Kingdom.
GP, General Practitioner ; STEC, Shiga toxin-producing E. coli O157; EPEC enteropathogenic Escherichia coli.
* Data from three provinces in Italy.
Campylobacter
Salmonella
DE DK IT NL PL SE UK
Fig. 4. Incidence of pathogen-speciﬁc gastroenteritis per 100 000 person-years, per layer of the surveillance pyramid. Upper
block: hospitalized cases ; middle block: cases visiting a General Practitioner ; lower block: non-consulting cases. Shaded
areas indicate reported cases. Figures are drawn to scale of the incidence rate in the general population. DE, Germany; DK,
Denmark; IT, Italy ; NL, The Netherlands ; PL, Poland; SE, Sweden; UK, United Kingdom.
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parameters are included. The CV in results for
DE was lower than for other countries, because the
uncertainty in the country-speciﬁc parameters was
smaller due to a larger sample size in the telephone
survey (see Annex A). The uncertainty in estimates for
STEC in DK was relatively large. This can be related
to relatively high uncertainty in the probability
of patients with bloody diarrhoea visiting a GP or
submitting a sample (see detailed results in Annex A).
The output distributions typically have a right-
hand tail, as the upper band is larger than the lower
band. Generally, means of the output distributions
were higher than medians, and even the median of the
output distributions was higher than a simple point
estimate of a deterministic calculation using the mean
values of all parameter uncertainty distributions.
Hence, including parameter uncertainty in the model
tends to inﬂuence the estimates for incidence rates to
higher values than deterministic estimates.
DISCUSSION
Overview of results
Annually, EFSA and ECDC report on routine
surveillance data from diﬀerent (European) countries
[32]. Such data are extracted from ‘Eavesdrop on’
the healthcare system which functions diﬀerently
in each country and is not designed to provide
harmonized information on disease incidence. It is
widely acknowledged that comparing such routinely
collected data needs to be done with utmost care.
Reconstructing the surveillance pyramid provides
important information for interpretation of reported
data, and provision of incidence estimates that can be
meaningfully compared. Such studies are attractive as
they are relatively easy to perform in comparison to
population-based surveys such as the IID studies in
the UK [4, 5] and the Sensor study in The Netherlands
[6]. Our results conﬁrm that the degree of under-
reporting varies widely by pathogen and by country.
The main factors that contribute to these varying
degrees of underreporting and under-diagnosis are
diﬀerences in healthcare usage and diﬀerences in
laboratory practice. Multipliers varied from 6.7 (Salm
in DE) to 2300 (Yers in UK). Overall, multipliers were
lowest for DE and SE and highest for PL.
Comparison with other reconstruction studies
Other authors have previously reported similar
studies to reconstruct the surveillance pyramid for
speciﬁc pathogens or for gastrointestinal illness in
general [1, 9, 11–13, 33]. The current study is more
comprehensive than previous studies, considering
seven enteric pathogens in seven countries. There
are, however, diﬀerences in the level of detail in the
actual calculations. As in the current study, three
published studies [9, 13, 33] applied diﬀerential
rates for patients with bloody and non-bloody
diarrhoea. One study also accounted for the duration
of illness as a determinant of seeking medical care
and of stool examination. None of the previously
published studies considered diﬀerences in reporting
rates for hospitalized and non-hospitalized patients,
and only one study attempted full uncertainty
analysis [13].
Limitations of this study
This study is the ﬁrst to attempt a multi-country
reconstruction of the surveillance pyramid. The
multipliers vary widely by country and by pathogen.
Further, the incidence rates vary widely between
countries, and there is considerable uncertainty. This
may at least, in part, be due to the uncertainties in
the parameters used to reconstruct the surveillance
pyramid. Nevertheless, the transparency of the model
allowed consideration of the diﬀerent steps in the
pyramid in more detail, in order to understand the
observed diﬀerences in multipliers. This demonstrated
that there are substantial diﬀerences in the proportion
of patients who visit their GP and that this factor
alone explains to a large extent diﬀerences in the
multiplier. This diﬀerence is propagated in the next
step of the pyramid, namely the proportion of GP
patients who submit a stool sample. These two steps
in the pyramid clearly have the largest impact on the
ﬁnal results. The impact of sample analysis and test
sensitivity is not large (and is more similar between
countries).
Our model is based on the key assumption that
bloody diarrhoea is an important determinant of
healthcare-seeking behaviour, and of seeking labora-
tory diagnosis. The diﬀerences between parameter
estimates as based on cross-sectional surveys in
participating countries and literature data [5, 19–22]
conﬁrm this hypothesis. However, case numbers with
bloody diarrhoea in the telephone surveys were quite
small, leading to considerable uncertainty in our re-
sults. Furthermore, other factors including presence
of pain, fever, duration of symptoms, education and
recent history of foreign travel, are reported to be at
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least as important and are not included in our
study [4, 34, 35]. The telephone surveys do not dis-
tinguish between viral and bacterial gastroenteritis.
Viral gastroenteritis typically has a milder and
shorter course than bacterial gastroenteritis, hence the
frequency of GP consultation and stool submission
may be lower than for bacterial (i.e. more severe)
gastroenteritis. This may lead to a general inﬂation
of all the multipliers and case estimates for all
countries.
Even though our parameter estimates for health-
care use and sample submission were based on a series
of coordinated cross-sectional surveys, other factors
in the reconstruction model were less well known and
were based on expert opinion. This resulted in con-
siderable uncertainty and potential biases in the inci-
dence estimates, that should be reduced by further
surveys, e.g. on laboratory practice. We also noted
that there is very little information on the sensitivity
of test methods applied in routine diagnostic lab-
oratories. Diagnostic algorithms may vary between
countries. Especially for STEC O157 diﬀerences in
laboratory practice and methods (culture and sero-
typing vs. Shiga toxin detection only) may have a
greater impact on correctly diagnosed and reported
cases compared to other pathogens. This may in part
explain diﬀerences in reported cases and, conse-
quently, diﬀerences in the incidence estimates between
countries.
In this study we combined surveillance data from
2001–2005 with survey data from 2008–2009. This
discrepancy may have aﬀected the incidence estimates
resulting from the pyramid reconstruction. However,
surveillance data have not changed much over the
time period between 2001–2009 [32]. Hence, we expect
that the results would be similar using more recent
surveillance data.
Furthermore, in this study a proxy data source for
all cases in the population outbreak data was used
to estimate the proportion of cases with bloody
diarrhoea. However, outbreak cases are only a small
fraction of all cases and they could easily over-
represent persons with more severe illness who visited
a GP.
Validity of the pyramid reconstruction
The validity of the pyramid reconstruction approach
can be explored by comparison with datasets from
independent studies: the IID studies in England
(IID1, 1993–1996 [27] ; IID2, 2008 [5] and the
Sensor/NIVEL studies in The Netherlands (1996–
1999) [6, 36]). Both countries organized large-scale
population-based cohort studies to observe the
incidence of infectious gastroenteritis and to analyse
its aetiology. Studies were performed in the general
population and in patients with gastroenteritis
who consulted their GP. Figure 5 gives a summary
of incidence data from these studies, compared to
the incidence estimates from the current study.
Overall, the incidence rates estimated by the pyramid
reconstruction approach are higher than those esti-
mated by prospective cohort studies. The correction
for sensitivity of laboratory analysis, which is in-
cluded in the pyramid reconstruction model explains
a 1.1–2 times higher incidence rate compared to the
cohort studies, where this correction is not made.
Nevertheless, estimates at population level for Camp,
Salm, Shig, and Cryp in the UK and Camp and
Cryp in NL are considerably higher than the
estimates for cohort studies. Possibly, the probability
of visiting a GP is underestimated for patients with
bacterial gastroenteritis if only bloody diarrhoea is
used as an explanatory factor. Other factors, such as
duration of illness, severity of symptoms and a high
proportion of young children among symptomatic
cases, may aﬀect consultation behaviour and should
be accounted for in future reconstruction studies.
The appropriateness of the model for the other
countries awaits further veriﬁcation by similar
population-based cohort studies or alternative study
designs.
Implications of this study for public health
Despite the remaining uncertainties, the pyramid re-
construction approach provides more realistic infor-
mation on the community incidence of gastroenteritis
due to speciﬁc pathogens in EU member states. This
study shows that each year millions of illnesses occur
in the European population, which lead to thousands
of hospitalizations. These estimates are a better basis
for comparing disease incidence in diﬀerent countries
than reported data, because the incidence estimates
obtained with the surveillance pyramid reconstruction
approach adjust for biases due to diﬀerent surveil-
lance systems.
The burden of illness is shown to be particularly
high for pathogens Camp and Salm. To a large extent,
these two pathogens are transmitted through food.
Hence, these estimates can also be used to assess food
safety management, which requires a consistent,
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quantitative assessment of the relative public health
impact of foodborne disease.
Furthermore, the incidence estimates obtained with
the pyramid reconstruction approach provide a better
basis for burden-of-disease estimates, quantiﬁed in
terms of disability-adjusted life years [7, 37], and for
estimating the public health beneﬁts and cost–beneﬁt
ratios of interventions supported by active surveil-
lance, aimed at reducing disease incidence.
APPENDIX. Additional members of the Working
Group
G. Adak (HPA), Y. Andersson (SMI), S. Ivarsson
(SMI), A. Ka¨sbohrer (BfR), A. Mac¸iag (PZH),
K. Mølbak (SSI), K. Stark (RKI), K. Sundstro¨m
(SLI), A. The´bault (ANSES), H. Wahlstro¨m (SVA),
B. van der Zanden (RIVM), A. Zielinski (PZH).
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